

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*
(incorporated in Bermuda with limited liability)
(Stock Code: 00512)

**SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE POLL RESULTS
OF THE ANNUAL GENERAL MEETING HELD ON 2 JUNE 2023**

Reference is made to the announcement (the “**Announcement**”) of Grand Pharmaceutical Group Limited (the “**Company**”) dated 2 June 2023 in relation to, amongst others, the poll results of the annual general meeting (the “**AGM**”) held on 2 June 2023. Unless stated otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

This announcement is made pursuant to Rule 13.39(5A) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited to provide supplemental information on the attendance of the Directors at the AGM. The chief executive officer of the Company and also being a director appointed during the AGM, Mr. Zhou Chao, attended the AGM, and other Directors did not attend the AGM due to other business engagements.

Save as disclosed above, all information and contents set out in the Announcement remain unchanged.

By order of the Board
Grand Pharmaceutical Group Limited
Dr. Tang Weikun
Chairman

Hong Kong, 7 June 2023

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao, Dr. Niu Zhanqi and Dr. Shi Lin, and three independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*